top of page
Single_Cell_Gradient_9a.png

Accession Therapeutics presented some of the exciting preclinical data for our lead programme

Accession Therapeutics presented some of the exciting preclinical data for our lead programme #TROCEPT-01 at the recent 37th Annual Meeting of the @Society for Immunotherapy of Cancer.


Working with our partners at @Cardiff University we demonstrated the potential of #TROCEPT products to generate high concentrations of potent anti-tumour drugs selectively in cancer cells with minimum systemic toxicity.


In in vitro and in vivo studies #TROCEPT-01 was shown to traffic to tumour cells highly selectively where its immune checkpoint inhibitor transgene was functionally expressed. Minimal levels of #TROCEPT-01 were detected outside of the tumour.


Read more about how #TROCEPT, a novel cancer-selective delivery technology, is powering our pipeline here.


@Journal for ImmunoTherapy of Cancer


112122_ECP_Accession
.pdf
Download PDF • 188KB





Comentarios


bottom of page